Progyny Management
Management criteria checks 3/4
Progyny's CEO is Pete Anevski, appointed in Jan 2022, has a tenure of 3.58 years. total yearly compensation is $1.36M, comprised of 57.3% salary and 42.7% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $9.10M. The average tenure of the management team and the board of directors is 3.6 years and 5.8 years respectively.
Key information
Pete Anevski
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 57.31% |
| CEO tenure | 3.6yrs |
| CEO ownership | 0.5% |
| Management average tenure | 3.6yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
At US$22.49, Is It Time To Put Progyny, Inc. (NASDAQ:PGNY) On Your Watch List?
Aug 02
Progyny (NASDAQ:PGNY) Might Have The Makings Of A Multi-Bagger
Jul 13Progyny: Robust Expectations In 2025 Amid Growing Expenses (Hold)
May 28Progyny, Inc.'s (NASDAQ:PGNY) CEO Will Probably Struggle To See A Pay Rise This Year
May 16The Price Is Right For Progyny, Inc. (NASDAQ:PGNY)
May 13At US$22.90, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?
Apr 25Progyny, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Mar 02The Play On Progyny: Don't Chase, But Watch And Wait
Feb 06Capital Allocation Trends At Progyny (NASDAQ:PGNY) Aren't Ideal
Jan 30Progyny: The Growth Story Remains Intact
Jan 15Progyny, Inc.'s (NASDAQ:PGNY) P/E Is Still On The Mark Following 28% Share Price Bounce
Jan 12Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Jan 03The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
Dec 31Progyny: Rating Downgrade On Uncertain Growth Outlook
Nov 26Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively
Nov 21Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
Nov 18Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital
Oct 21Progyny: Poor Year Raises Concerns For Future (Downgrade)
Oct 15Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors
Sep 29
Expanding Market Reach And Enhancing Services Spur Optimistic Revenue And Profit Forecasts
Anticipated decrease in ART cycle utilizations may negatively affect revenue due to lower fertility treatment rates.Progyny: Downgrading As Uncertainties Increase
Aug 15Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing
Aug 11At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?
Jul 20Progyny: Recent Stock Decline Provides Buying Opportunity
Jul 12Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall
Jun 23Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore
Jun 10Progyny: No Change To Long-Term Outlook
Jun 04Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price
Apr 29Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Apr 03Progyny: Long-Term Outlook Remains Positive, Reiterate Buy
Mar 15Progyny: Long-Term Thesis Still Intact
Mar 09Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher
Mar 01Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable
Jan 07Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Dec 11Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)
Nov 08Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Aug 24There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital
Aug 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | US$53m |
| Mar 31 2025 | n/a | n/a | US$52m |
| Dec 31 2024 | US$1m | US$780k | US$54m |
| Sep 30 2024 | n/a | n/a | US$57m |
| Jun 30 2024 | n/a | n/a | US$63m |
| Mar 31 2024 | n/a | n/a | US$61m |
| Dec 31 2023 | US$1m | US$500k | US$62m |
| Sep 30 2023 | n/a | n/a | US$52m |
| Jun 30 2023 | n/a | n/a | US$49m |
| Mar 31 2023 | n/a | n/a | US$43m |
| Dec 31 2022 | US$69m | US$500k | US$30m |
| Sep 30 2022 | n/a | n/a | US$42m |
| Jun 30 2022 | n/a | n/a | US$46m |
| Mar 31 2022 | n/a | n/a | US$56m |
| Dec 31 2021 | US$786k | US$425k | US$66m |
| Sep 30 2021 | n/a | n/a | US$90m |
| Jun 30 2021 | n/a | n/a | US$78m |
| Mar 31 2021 | n/a | n/a | US$58m |
| Dec 31 2020 | US$910k | US$425k | US$46m |
| Sep 30 2020 | n/a | n/a | US$3m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$5m | US$375k | -US$9m |
| Sep 30 2019 | n/a | n/a | -US$6m |
| Jun 30 2019 | n/a | n/a | US$1m |
| Mar 31 2019 | n/a | n/a | -US$4m |
| Dec 31 2018 | US$682k | US$325k | -US$6m |
Compensation vs Market: Pete's total compensation ($USD1.36M) is below average for companies of similar size in the US market ($USD5.97M).
Compensation vs Earnings: Pete's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Pete Anevski (58 yo)
Mr. Peter Anevski, also known as Pete, has been Chief Executive Officer and Director of Progyny, Inc. since January 2022 and had been its President since June 2019 until December 31, 2021 and was its Chief...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 8.4yrs | US$468.17k | 0.25% $ 5.0m | |
| CEO & Director | 3.6yrs | US$1.36m | 0.45% $ 9.1m | |
| President | 3.6yrs | US$21.53m | 0.15% $ 3.0m | |
| Chief Financial Officer | 4.9yrs | US$2.14m | 0.021% $ 415.3k | |
| Executive VP | 2.8yrs | US$1.93m | 0.031% $ 621.5k | |
| Chief Operating Officer | less than a year | no data | no data | |
| Chief Technology Officer | 1.6yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Marketing Officer | no data | no data | no data | |
| Chief Human Resources Officer | no data | no data | no data | |
| Chief Business Development Officer | 3.6yrs | no data | no data | |
| Member of the Medical Advisory Board & Chief Medical Officer | 2.3yrs | no data | no data |
Experienced Management: PGNY's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 8.4yrs | US$468.17k | 0.25% $ 5.0m | |
| CEO & Director | 3.6yrs | US$1.36m | 0.45% $ 9.1m | |
| Member of the Medical Advisory Board & Chief Medical Officer | no data | no data | no data | |
| Independent Director | 8.7yrs | US$567.30k | 0.48% $ 9.6m | |
| Independent Director | 10.4yrs | US$583.37k | 0.019% $ 386.5k | |
| Independent Director | 5.8yrs | US$518.33k | 0.015% $ 292.5k | |
| Independent Director | 5.8yrs | US$518.33k | 0.0086% $ 173.6k | |
| Lead Independent Director | 5.8yrs | US$609.39k | 0.019% $ 386.5k | |
| Member of the Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
Experienced Board: PGNY's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/18 07:08 |
| End of Day Share Price | 2025/08/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Progyny, Inc. is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhilin Long | Berenberg |
| Nisala Weerasuriya | Berenberg |
| Allen Lutz | BofA Global Research |